LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastric cancer (GC) is a heterogeneous disease with poorly understood long non-coding RNA (lncRNA) roles.
• Microsatellite stable (MSS)/epithelial-mesenchymal transition (EMT) GC is aggressive and linked to poor outcomes.

Purpose of the Study:

• To investigate lncRNA heterogeneity across GC subtypes.
• To identify master regulators of EMT in MSS/EMT GC.
• To elucidate the functional role and mechanism of MIR200CHG in MSS/EMT GC.

Main Methods:

• Integrated network analysis of lncRNA expression in GC subtypes.
• In vitro cell culture experiments to assess MIR200CHG function.
• In vivo metastasis assays.
• Analysis of MIR200CHG's role in miRNA biogenesis and stability.

Main Results:

• MIR200CHG identified as a master regulator of EMT specifically in MSS/EMT GC.
• MIR200CHG expression is silenced by promoter hypermethylation in MSS/EMT GC, correlating with poor prognosis.
• MIR200CHG inhibits GC cell mesenchymal identity and metastasis in vitro and in vivo.
• MIR200CHG promotes miR-200c and miR-141 biogenesis and protects miR-200c from degradation.

Conclusions:

• MIR200CHG acts as a tumor suppressor in MSS/EMT GC by reversing EMT and inhibiting metastasis.
• MIR200CHG's epigenetic silencing contributes to aggressive GC phenotypes.
• MIR200CHG's dual role in miRNA regulation provides novel insights into GC pathogenesis.